Publications associées à Interactions médicaments-pamplemousse

Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy

Olivier Michielin, Federico Amato, Monia Guidi, Nadia Terranova, Daniel Abler, Alexandre Wicky

The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy but only a fraction of patients benefits from this therapy. Model-informed drug development can be used to assess prognostic and predictive clinical factors or biomark ...

2023

NICEdrug.ch, a workflow for rational drug design and systems-level analysis of drug metabolism

Vassily Hatzimanikatis, Jasmin Maria Hafner, Homa Mohammadi Peyhani, Noushin Hadadi, Anush Chiappino-Pepe

The discovery of a drug requires over a decade of intensive research and financial investments – and still has a high risk of failure. To reduce this burden, we developed the NICEdrug.ch resource, which incorporates 250,000 bioactive molecules, and studied ...

2021

Structures of ABCG2 under turnover conditions reveal a key step in the drug transport mechanism

Henning Paul-Julius Stahlberg, Dongchun Ni

ABCG2 is a multidrug transporter that affects drug pharmacokinetics and contributes to multidrug resistance of cancer cells. In previously reported structures, the reaction cycle was halted by the absence of substrates or ATP, mutation of catalytic residue ...

Nature Research2021

Outer membrane lipoprotein NlpI scaffolds peptidoglycan hydrolases within multi-enzyme complexes in Escherichia coli

Ann-Kristin Hov

The peptidoglycan (PG) sacculus provides bacteria with the mechanical strength to maintain cell shape and resist osmotic stress. Enlargement of the mesh-like sacculus requires the combined activity of peptidoglycan synthases and hydrolases. In Escherichia ...

WILEY2020

Enhancing the Signaling of GPCRs via Orthosteric Ions

Horst Vogel, Shuguang Yuan

G protein-coupled receptors play essential roles in cellular processes such as neuronal signaling, vision, olfaction, tasting, and metabolism. As GPCRs are the most important drug targets, understanding their interactions with ligands is of utmost importan ...

AMER CHEMICAL SOC2020

Do chance encounters between heterogeneous cells shape the outcome of tuberculosis infections?

John McKinney, Ophélie Rutschmann, Chiara Toniolo

The sum of all of the interactions between single bacteria and host cells determines if an infection is cleared, controlled, or progresses at the whole host-organism level. These individual interactions have independent trajectories defined by diverse and ...

2020

Graphene nanowalls for high-performance chemotherapeutic drug sensing and anti-fouling properties

Giovanni De Micheli, Ioulia Tzouvadaki, Sandro Carrara, Nima Aliakbarinodehi

Improved sensitivity and continuous monitoring of therapeutic compounds are two of the most highlighted concerns for the treatment of malignant diseases, such as cancer. We demonstrated ultrasensitive screening of etoposide, a therapeutic compound widely-u ...

2018

More Medicines for Tuberculosis: Fuelling Drug Discovery against Mycobacterium tuberculosis

Shi-Yan Caroline Foo

Tuberculosis (TB), whose etiological agent is Mycobacterium tuberculosis (M. tuberculosis), has plagued humanity since antiquity. Even with chemotherapy available today, TB is the leading cause of death due to an infectious disease. Modern day factors, suc ...

EPFL2018

Ultra Selective and Sensitive Electrochemical Detection of Anti-Cancer and Anti-Viral Drugs by Optimized Nano-Bio-Sensors

Nima Aliakbarinodehi

Reliable, low cost, and accessible drug monitoring systems for individualized healthcare, especially chemotherapy for malignant diseases like prostate cancer and AIDS, are highly desira-ble. This is even more critical for drugs like abiraterone and TFV, wi ...

EPFL2017

Controlling and Monitoring Intracellular Delivery of Anticancer Polymer Nanomedicines

Harm-Anton Klok, Claudia Battistella

Polymer nanomedicines are very attractive to improve the delivery of chemotherapeutics. Polymer conjugates and other polymer-based nanocarriers allow to increase plasma half-life and drug bioavailability and can also be guided toward tumors using passive a ...

2017